SIHUAN PHARM HLDGS ADR - $SHPHY STOCK NEWS

Welcome to our dedicated page for SIHUAN PHARM HLDGS ADR news (Ticker: $SHPHY), a resource for investors and traders seeking the latest updates and insights on SIHUAN PHARM HLDGS ADR stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SIHUAN PHARM HLDGS ADR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SIHUAN PHARM HLDGS ADR's position in the market.

10/14/2023 08:09 AM

News

Sihuan Pharmaceutical Was Selected As One Of The First Echelon Of Enterprises In The list of China's Top 100 Pharmaceutical Innovative Enterprises in 2023

Rhea-AI Summary

Sihuan Pharmaceutical Holdings Group has been selected as one of the first echelon of enterprises in China's Top 100 Pharmaceutical Innovative Enterprises in 2023. The selection was based on patent data and aims to explore innovation power in the industry.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

06/27/2023 09:57 PM

News

Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical, Its Innovative Drug Anaprozole Sodium Enteric-coated Tablets Obtains Drug Registration Approval From NMPA

Rhea-AI Summary

Sihuan Pharmaceutical Holdings Group Ltd's subsidiary, Xuanzhu Biopharmaceutical Co., Ltd., has received drug registration approval from the NMPA of China for Anaprozole Sodium Enteric-coated Tablet. It is the first drug approved for marketing by Xuanzhu Biopharm and is used for the treatment of duodenal ulcer. The tablet is the first and only PPI fully developed in China and has fast onset, stable therapeutic effect, and low risk of drug interactions. It is also expanding its indication for the treatment of adult reflux esophagitis. The approval is expected to bring more treatment options for patients and inject billions of dollars into the acid suppressant market.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %